🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 409306 25 mg

Found 11 matching trials

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

PHASE2

The objective of the study is to investigate the efficacy, safety and toler...

Status

Terminated

Location

Alea Research

Start Date

2017-12-07

Trial ID

NCT03351244

Treatments Being Tested

BI 409306 Placebo

Safety Tolerability and Pharmacokinetic of BI 409306

PHASE1

The primary objective of the current study is to investigate the safety and...

Status

Completed

Location

1289.1.1 Boehringer Ingelheim Investigational Site

Start Date

2011-04-01

Trial ID

NCT01343706

Treatments Being Tested

Placebo Placebo BI 409306 BI 409306

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

PHASE1

Single site, parallel-group, double-blind trial of low or high dose of BI 4...

Status

Completed

Location

University of California San Diego

Start Date

2015-04-15

Trial ID

NCT02392468

Treatments Being Tested

Placebo matching BI 409306 25 mg Placebo matching BI 409306 50 mg BI 409306 25 mg BI 409306 50 mg

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

PHASE2

The objective of the study is to investigate the efficacy, safety and toler...

Status

Completed

Location

K and S Professional Research Services, LLC

Start Date

2014-11-10

Trial ID

NCT02281773

Treatments Being Tested

BI 409306 100 mg QD BI 498306 50 mg QD Placebo BI 498306 25 mg QD BI 409306 10 mg QD

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

PHASE1

The primary objective of this trial was to investigate safety and tolerabil...

Status

Completed

Location

1289.2.1 Boehringer Ingelheim Investigational Site

Start Date

2012-01-01

Trial ID

NCT01505894

Treatments Being Tested

BI 409306 Placebo

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

PHASE1

The aim of this study is to assess the mass balance recovery from excreta o...

Status

Completed

Location

Quotient Sciences

Start Date

2015-09-15

Trial ID

NCT02597998

Treatments Being Tested

14C-BI 409306

Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers

PHASE1

To evaluate the effect of food on the pharmacokinetics of BI 409306 and to ...

Status

Completed

Location

1289.22.1 Boehringer Ingelheim Investigational Site

Start Date

2014-09-04

Trial ID

NCT02222168

Treatments Being Tested

BI 409306

Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers

PHASE1

Safety, tolerability and pharmacokinetics of single and multiple oral doses...

Status

Completed

Location

1289.4.8201 Boehringer Ingelheim Investigational Site

Start Date

2013-04-22

Trial ID

NCT01841112

Treatments Being Tested

Placebo BI-409306 25 milligram (mg) SD BI-409306 50 mg SD BI-409306 100 mg SD BI-409306 100 mg MD

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306

PHASE1

The primary objective of the current study is to investigate the safety and...

Status

Completed

Location

1289.17.1 Boehringer Ingelheim Investigational Site

Start Date

2012-05-01

Trial ID

NCT01611311

Treatments Being Tested

BI 409306 Placebo

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

PHASE1

The objective of the current study is to evaluate the effect of once daily ...

Status

Completed

Location

1289.23.8201 Boehringer Ingelheim Investigational Site

Start Date

2014-10-08

Trial ID

NCT02248259

Treatments Being Tested

BI 409306 Itraconazole

Previous Next